Exemestane (Aromasin) 25mg is an aromatase inhibitor used to lower estrogen levels and support the treatment of certain estrogen sensitive conditions. Each pack contains 30 tablets.
Format30 Tablets
Concentration25mg
Pay with Interac e-Transfer or Crypto
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
Exemestane, marketed under the pharmaceutical brand name Aromasin, is a third generation steroidal aromatase inhibitor with FDA approval for breast cancer treatment and the only steroidal aromatase inhibitor among the third generation AI compounds, a structural distinction that produces a fundamentally different mechanism of action from the non steroidal aromatase inhibitors Anastrozole and Letrozole. This formulation delivers 25mg per tablet in a 30 count format, consistent with the concentration most commonly referenced in aromatase inhibition and estrogen biosynthesis research literature.
Exemestane’s steroidal structure is the defining pharmacological characteristic that differentiates it from Anastrozole within CSD’s aromatase inhibitor range. Anastrozole is a non steroidal competitive and reversible aromatase inhibitor. Tt competes with androgens for CYP19A1 enzyme binding but does not permanently alter the enzyme. Exemestane is a steroidal mechanism based irreversible aromatase inactivator. Its androstenedione derived structure allows it to bind the aromatase active site and form a permanent covalent bond with the enzyme, irreversibly inactivating it. This irreversible mechanism produces aromatase suppression that persists until new enzyme is synthesized; a pharmacological distinction from reversible inhibitors that has generated specific comparative research into the clinical and biological differences between reversible competitive inhibition and irreversible mechanism based inactivation across aromatase enzyme activity studies.
Exemestane’s steroidal androstenedione derived structure also produces a secondary androgenic metabolitel 17-hydroexemestane; which carries weak androgenic activity through androgen receptor binding. This androgenic metabolite activity is unique among aromatase inhibitors and absent from non steroidal alternatives like Anastrozole, generating specific research interest in the differential effects of steroidal versus non steroidal aromatase inhibition on androgen receptor activity, bone metabolism, and lipid profiles in comparative AI research. CSD stocks both Exemestane and Anastrozole. Allows researchers access to both irreversible steroidal and reversible non steroidal aromatase inhibition mechanisms from a single verified Canadian supplier for complete comparative AI research coverage.
Every batch of CSD’s Exemestane is third party lab tested for concentration accuracy and purity before being made available, with COA documentation available on request. Canada Steroid Depot has supplied Canadian customers with consistently verified, accurately dosed research compounds for years, and our estrogen management range: Anastrozole, Exemestane, Tamoxifen, Clomiphene, Enclomiphene, and Raloxifene. Products cover aromatase inhibition and SERM estrogen regulation research from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Store in a cool, dry place away from direct light and heat. Intended for research purposes only.
Commonly researched alongside Anastrozole in comparative steroidal versus non steroidal aromatase inhibitor studies. Browse CSD’s full PCT and hormone research range for complete sourcing.
Exemestane is a prescription steroidal aromatase inhibitor marketed under the brand name Aromasin. It reduces estrogen production by irreversibly inactivating the aromatase enzyme responsible for converting androgens into estrogens. Each tablet contains 25mg of exemestane, with 30 tablets supplied per package for 750mg total.
Exemestane is used in postmenopausal women for certain hormone receptor positive breast cancers. Approved uses include adjuvant treatment of early breast cancer after initial tamoxifen therapy and treatment of advanced breast cancer that has progressed following tamoxifen therapy. Treatment should be directed by an appropriate healthcare professional.
Exemestane acts as an irreversible steroidal aromatase inactivator. Aromatase is the enzyme responsible for converting androgen precursors into estrogens in peripheral tissues. By permanently binding to and inactivating aromatase molecules, exemestane substantially reduces circulating estrogen concentrations until new aromatase enzyme is produced.
Both exemestane and anastrozole reduce estrogen production by targeting aromatase, but they belong to different classes. Exemestane is a steroidal irreversible aromatase inactivator, whereas anastrozole is a non steroidal reversible aromatase inhibitor. Their ultimate effect is reduced estrogen synthesis, but the way they interact with the aromatase enzyme differs.
Exemestane can substantially lower estrogen concentrations and may reduce bone mineral density, so bone health can require monitoring during treatment. Other considerations include changes in cholesterol, liver abnormalities, and potential interactions with strong CYP3A4 inducing medications. Exemestane can cause fetal harm and is intended for appropriate patients under medical supervision.
![PRAMIPEXOLE 1MG X 100 [PARKINSON'S]](https://www.canadasteroiddepot.is/wp-content/uploads/2025/09/PRAMIPEXOLE-1-X-100-300x300.webp)
![RALOXIFENE 60MG X 100 [BONE HEALTH]](https://www.canadasteroiddepot.is/wp-content/uploads/2025/07/RALOXIFENE-60-X-100-300x300.webp)
